{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:17:51Z","timestamp":1787696271593,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003878"],"award-info":[{"award-number":["82003878"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["H2024206062"],"award-info":[{"award-number":["H2024206062"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.numecd.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:26:42Z","timestamp":1730093202000},"page":"103779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhiling","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-4297","authenticated-orcid":false,"given":"Congxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2024.10.017_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-021-00190-z","article-title":"Genetic basis of hypercholesterolemia in adults","volume":"6","author":"Saadatagah","year":"2021","journal-title":"npj Genom Med"},{"key":"10.1016\/j.numecd.2024.10.017_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2009.02.017","article-title":"The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis","volume":"31","author":"Delahoy","year":"2009","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.numecd.2024.10.017_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.10.017_bib4","article-title":"Comparative effectiveness of inclisiran 100, 300, and 500 mg in a population with hyperlipidemia: a network meta-analysis of randomized controlled trials","volume":"18","author":"Y","year":"2018","journal-title":"Am J Cardiovasc Drugs : drugs, devices, and other interventions"},{"key":"10.1016\/j.numecd.2024.10.017_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.numecd.2024.10.017_bib6","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.10.017_bib7","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.10.017_bib8","volume":"vol. 11","author":"Ray","year":"2023"},{"key":"10.1016\/j.numecd.2024.10.017_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","article-title":"First clinical experiences with inclisiran in a real-world setting","volume":"17","author":"Mulder","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2024.10.017_bib10","article-title":"Effectiveness and safety of Inclisiran in hyperlipidemia treatment: an overview of systematic reviews","volume":"102","author":"Li","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.numecd.2024.10.017_bib11","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib12","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/CIRCRESAHA.117.310610","article-title":"A new approach to PCSK9 therapeutics","volume":"120","author":"Wang","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2024.10.017_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.numecd.2024.10.017_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.numecd.2024.10.017_bib15","doi-asserted-by":"crossref","DOI":"10.5551\/jat.64454","article-title":"Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15","author":"Yamashita","year":"2024","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2024.10.017_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.10.017_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.10.017_bib18","doi-asserted-by":"crossref","unstructured":"Raal F, Durst R, Bi R et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation 0, DOI: 10.1161\/CIRCULATIONAHA.122.063460.","DOI":"10.1161\/CIRCULATIONAHA.122.063460"},{"key":"10.1016\/j.numecd.2024.10.017_bib19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.10.017_bib20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.10.017_bib21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacl.2023.04.010","article-title":"The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia","volume":"17","author":"Luo","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2024.10.017_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in asian patients: results from ORION-18","volume":"4","author":"Huo","year":"2024","journal-title":"JACC Asia"},{"key":"10.1016\/j.numecd.2024.10.017_bib23","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.10.017_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.numecd.2024.10.017_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002184","article-title":"Lipid lowering with inclisiran: a real-world single-centre experience","volume":"9","author":"Padam","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.numecd.2024.10.017_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clinthera.2023.12.003","article-title":"First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a Middle East population","volume":"46","author":"Iqbal","year":"2024","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.numecd.2024.10.017_bib29","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/eurjpc\/zwac025","article-title":"Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia","volume":"29","author":"Reijman","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib30","article-title":"Meta-analysis of inclisiran for the treatment of hypercholesterolemia","volume":"134","author":"Sa","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib31","first-page":"1","article-title":"A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients","author":"Dutta","year":"2023","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.numecd.2024.10.017_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.amjcard.2020.05.024","article-title":"A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran","volume":"128","author":"Asbeutah","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib33","article-title":"Serious adverse events of Inclisiran in patients with hypercholesterolemia, a meta analysis of ORION trials","author":"Jawwad","year":"2023","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.numecd.2024.10.017_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.numecd.2024.10.017_bib35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.numecd.2024.10.017_bib36","article-title":"Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies","volume":"13","author":"Cicero","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2024.10.017_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1158274","article-title":"Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.numecd.2024.10.017_bib38","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/cts.13391","article-title":"An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: a phase I, randomized study","volume":"15","author":"Kallend","year":"2022","journal-title":"Clin Transl Sci"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324003983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324003983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:37:26Z","timestamp":1762331846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475324003983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0939475324003983"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.10.017","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103779"}}